REVIEW PAPER
Psoriasis in special localizations
Submission date: 2018-11-04
Final revision date: 2018-12-03
Acceptance date: 2018-12-05
Online publication date: 2018-12-23
Publication date: 2018-12-23
Reumatologia 2018;56(6):392-398
KEYWORDS
TOPICS
ABSTRACT
Psoriasis is a chronic inflammatory dermatosis affecting 1–3% of the general population. Patients with psoriasis represent a heterogeneous population with individual disease expression – different degrees and severity of skin involvement. Psoriatic lesions in particular localizations such as the face, scalp, intertriginous or palmoplantar areas significantly reduce quality of life. Patients often feel ashamed, embarrassed, or self-conscious about their symptoms. Furthermore, genital psoriasis significantly affects sexual health. Among patients with psoriasis, the prevalence of special localizations is estimated to be 23–27% on the nails, 49% on the face, 12–16% on the palms and soles, and up to 36% in intertriginous regions. Due to peculiar features of skin in these areas, adequate and specific management is required, which is discussed in this review.
REFERENCES (44)
1.
Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol 2017; 31: 205-212.
2.
Reich A, Adamski Z, Chodorowska G, et al. Psoriasis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part I: Mild psoriasis. Dermatol Rev/Przegl Dermatol 2018; 105: 225-243.
3.
Merola JF, Li T, Li W, et al. Prevalence of psoriasis phenotypes among men and women in the USA. Clin Exp Dermatol 2016; 41: 486-489.
4.
Aldredge LM, Higham RC. Manifestations and Management of Difficult-to-Treat Psoriasis. JDNA 2018; 10: 189-197.
5.
Frez ML, Asawanonda P, Gunasekara C, et al. Recommendations for a patient-centered approach to the assessment and treatment of scalp psoriasis: A consensus statement from the Asia Scalp Psoriasis Study Group. J Dermatolog Treat 2014; 25: 38-45.
6.
Sampogna F, Linder D, Piaserico S, et al. Quality of life assessment of patients with scalp dermatitis using the Italian version of the Scalpdex. Acta Derm Venereol 2014; 94: 411-414.
7.
Alpsoy E, Polat M, Fettahlio Glu-Karaman B, et al. Internalized stigma in psoriasis: A multicenter study. J Dermatol 2017; 44: 885-891.
8.
Woo SM, Choi JW, Yoon HS, et al. Classification of facial psoriasis based on the distributions of facial lesions. J Am Acad Dermatol 2008; 58: 959-963.
9.
Canpolat F, Cemil BC, Eskioglu F, Akis HK. Is facial involvement a sign of severe psoriasis? Eur J Dermatol 2008; 18: 169-171.
10.
Van de Kerkhof PCM, Murphy GM, Austad J, et al. Psoriasis of the face and flexures. J Dermatolog Treat 2007; 18: 351-360.
11.
Omland SH, Gniadecki R. Psoriasis inversa: A separate identity or a variant of psoriasis vulgaris? Clin Dermatol 2015; 33: 456-461.
12.
Fan X, Yang S, Sun LD, et al. Comparison of clinical features of HLA-Cw*0602-positive and -negative psoriasis patients in a Han Chinese population. Acta Derm Venereol 2007; 87: 335-340.
13.
Wang G, Li C, Gao T, et al. Clinical analysis of 48 cases of inverse psoriasis: A hospital-based study. Eur J Dermatol 2005; 15: 176-178.
14.
Dubertret L, Mrowietz U, Ranki A, et al. European patient perspectives on the impact of psoriasis: The EUROPSO patient membership survey. Br J Dermatol 2006; 155: 729-736.
15.
Fouere S, Adjadj L, Pawin H. How patients experience psoriasis: Results from a European survey. J Eur Acad Dermatol Venereol 2005; 3 (Suppl 19): 2-6.
16.
Meeuwis KA, van de Kerkhof PC, Massuger LF, et al. Patients’ experience of psoriasis in the genital area. Dermatology 2012; 224: 271-276.
17.
Wozel G. Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas. Clin Dermatol 2008; 26: 448-459.
18.
Khosravi H, Siegel MP, Van Voorhees AS, Merola JF. Treatment of Inverse/Intertriginous Psoriasis: Updated Guidelines from the Medical Board of the National Psoriasis Foundation.
20.
Sarma N. Evidence and Suggested Therapeutic Approach in Psoriasis of Difficult-to-treat Areas: Palmoplantar Psoriasis, Nail Psoriasis, Scalp Psoriasis, and Intertriginous Psoriasis. Indian J Dermatol 2017; 62: 113-122.
21.
Kreuter A, Sommer A, Huyn J, et al. 1% Pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis. Arch Dermatol 2006; 142: 1138-1143.
22.
Dubweb GA, Eldebani S, Alhaddar J. Calcipotriol cream in the treatment of flexural psoriasis. Int J Tissue React 2003; 4: 127-130.
23.
Lebwohl M, Freeman AK, Chapman MS, et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 2004; 51: 723-730.
24.
Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: Nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther 2018; 31: e12589.
25.
Beck KM, Yang EJ, Sanchez IM, Liao W. Treatment of Genital Psoriasis: A Systematic Review. Dermatol Ther (Heidelb) 2018; 8: 509-525.
26.
Meeuwis KAP, Potts Bleakman A, van de Kerkhof PCM, et al. Prevalence of genital psoriasis in patients with psoriasis. J Dermatolog Treat 2018; 29: 754-760.
27.
Meeuwis KA, de Hullu JA, Massuger LF, et al. Genital psoriasis: a systematic literature review on this hidden skin disease. Acta Derm Venereol 2011; 91: 5-11.
28.
Yang EJ, Beck KM, Sanchez IM, et al. The impact of genital psoriasis on quality of life: a systematic review. Psoriasis (Auckl) 2018; 8: 41-47.
29.
Cather JC, Ryan C, Meeuwis K, et al. Patients’ perspectives on the impact of genital psoriasis: a qualitative study. Dermatol Ther 2017; 7: 447-461.
30.
Ryan C, Sadlier M, de Vol E, et al. Genital psoriasis is associated with significant impairment in quality of life and sexual functioning. J Am Acad Dermatol 2015; 72: 978-983.
31.
Welsh BM, Berzins KN, Cook KA, et al. Management of common vulval conditions. Med J Aust 2003; 178: 391-395.
32.
Albert S, Neill S, Derrick EK, et al. Psoriasis associated with vulval scarring. Clin Exp Dermatol 2004; 29: 354-356.
33.
Ryan C, Menter A, Guenther L, et al. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. Br J Dermatol 2018; 179: 844-852.
34.
Kragballe K. Management of Difficult to Treat Locations of Psoriasis Scalp, Face, Flexures, Palm/Soles and Nails. Curr Probl Dermatol 2009; 38: 160-171.
35.
Sanchez IM, Sorenson E, Levin E, Liao W. The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review. Dermatol Ther (Heidelb) 2017; 7: 425-446.
36.
Poulin Y, Crowley JJ, Langley RG, et al. Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH. J Eur Acad Dermatol Venereol 2013; 28: 882-890.
37.
Carrascosa JM, Plana A, Ferrándiz C. Effectiveness and safety of psoralen-UVA (PUVA) topical therapy in palmoplantar psoriasis: a report on 48 patients. Actas Dermosifiliogr 2013; 104: 418-425.
38.
Chen X, Yang M, Cheng Y, et al. Narrow-band ultraviolet B phototherapy versus broad-band ultraviolet B or psoralen-ultraviolet A photochemotherapy for psoriasis. Cochrane Database Syst Rev 2013; (10): CD009481.
39.
Goldberg DJ, Chwalek J, Hussain M. 308-nm Excimer laser treatment of palmoplantar psoriasis. J Cosmet Laser Ther 2011; 13: 47-49.
40.
Bissonnette R, Pariser DM, Wasel NR, et al. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis. J Am Acad Dermatol 2016; 75: 99-105.
41.
Janagond AB, Kanwar AJ, Handa S. Efficacy and safety of systemic methotrexate vs. acitretin in psoriasis patients with significant palmoplantar involvement: a prospective, randomized study. J Eur Acad Dermatol Venereol 2013; 27: e384-389.
42.
Bissonnette R, Poulin Y, Guenther L, et al. Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study. J Eur Acad Dermatol Venereol 2011; 25: 1402-1408.
43.
Busse K, Liao W. Which Psoriasis Patients Develop Psoriatic Arthritis? Psoriasis Forum 2010; 16: 17-25.
44.
Patrizi A, Venturi M, Scorzoni R, et al. Nail dystrophies, scalp and intergluteal/perianal psoriatic lesions: risk factors for psoriatic arthritis in mild skin psoriasis? G Ital Dermatol Venereol 2014; 149: 177-184.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
